LB PHARMACEUTICALS INC
LBRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LBRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LBRX
LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, LB-102, for the treatment of schizophrenia, with no approved products or revenue to date.
Key risk: Single product dependency
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials · 4 catalysts for LB PHARMACEUTICALS INC.
LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, LB-102, for the treatment of schizophrenia, with no approved products or revenue to date.
- Lead product candidate LB-102 is in clinical development for schizophrenia, with Phase 3 topline data expected around 2027-10-01 [sec_mda].
- Cash, cash equivalents and marketable securities were $327.8M as of June 30, 2026, excluding $150M from a July 2026 private placement [sec_mda · as of 2026-08-11].
- Net loss was $51.6M for the six months ended June 30, 2026 [sec].
- Accumulated deficit was $148.6M as of March 31, 2026 [sec_mda · as of 2026-05-12].
- The company expects existing cash to fund operations into the second quarter of 2029 [sec_mda · as of 2026-05-12].
What works
- Cash runway extended into Q2 2029, providing a multi-year development horizon without near-term financing pressure [sec_mda · as of 2026-05-12].
- LB-102 is advancing through Phase 3 trials, a late-stage asset with a defined regulatory path [sec_mda · as of 2026-08-11].
- The company has raised significant capital ($100M private placement in Feb 2026, $150M in July 2026) to support clinical development [sec_mda · as of 2026-08-11].
What to weigh
- No approved products or revenue from product sales; the company has incurred recurring losses since inception [sec_mda · as of 2026-05-12].
- Accumulated deficit of $148.6M as of March 31, 2026, with net losses expected to continue for the foreseeable future [sec_mda · as of 2026-05-12].
- Dependence on the success of a single lead candidate, LB-102; failure in clinical trials would materially harm the business [sec · filed 2026-06-10].
- Substantial additional funding will be needed to complete development, seek regulatory approval, and commercialize any product candidate [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
The company has no approved products and has incurred recurring losses since inception.
“We have not generated any revenue from product sales and we have incurred recurring losses since our inception.”
SEC MD&A · May 12, 2026
Cash runway is expected to fund operations into Q2 2029.
“we believe that our existing cash, cash equivalents and marketable securities, will be sufficient to meet our anticipated operating and capital expenditure requirements into the second quarter of 2029.”
SEC MD&A · May 12, 2026
The company is dependent on the success of LB-102.
“the Company's dependence on the success of its lead product candidate, LB-102”
SEC filings · June 10, 2026
Net loss for the three months ended March 31, 2026 was $19.1 million.
“Our net losses were $19.1 million and $5.3 million for the three months ended March 31, 2026 and 2025, respectively.”
SEC MD&A · May 12, 2026
Catalyst timeline
- 2027-10-01 · Phase3_Topline — Topline results from a randomized, double-blind, placebo-controlled Phase 3 study of LB-102 in schizophrenia.
- 2028-03-31 · Phase2_Topline · lb-102 — Phase 2 readout for LB-102, providing early efficacy and safety data.
- 2029-04-01 · Phase3_Topline · lb-102 — Topline results from a 52-week open-label safety and tolerability study of LB-102 in schizophrenia.
- 2029-06-30 · Phase2_Topline · lb-102 — Additional Phase 2 readout for LB-102.
Risks & what to watch (4)›
Key risks
- Single product dependency — Business depends on LB-102; clinical or regulatory failure would materially harm the company [sec · filed 2026-06-10].
- No revenue, recurring losses — No approved products or product revenue; net losses and negative cash flows expected to continue [sec_mda · as of 2026-05-12].
- Need for additional capital — Substantial additional funding required to complete development and commercialization [sec_mda · as of 2026-08-11].
- Clinical trial risks — Failure to replicate positive preclinical/clinical results in later trials could prevent regulatory approval [sec_mda · as of 2026-03-26].
What to watch
- Phase 3 topline data for LB-102 in schizophrenia, expected around 2027-10-01 [catalyst_timeline].
- Phase 2 readout for LB-102, expected around 2028-03-31 [catalyst_timeline].
- Cash burn rate and any additional financing activities as the company advances LB-102 through late-stage trials [sec_mda · as of 2026-08-11].
- Regulatory interactions and updates on the development timeline for LB-102 [sec_mda · as of 2026-08-11].
Sources: SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run LB PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LB PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
26.7 months
D/E 0.09 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
4 upcoming, next in ~397d
1 buy · 0 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
72
Total value held
$566.1M
| Holder | Shares | Value |
|---|---|---|
| deep track capital, lp | 3,352,804 | $82.7M |
| blackrock, inc. | 2,470,845 | $60.9M |
| ra capital management, l.p. | 2,208,604 | $54.5M |
| vanguard capital management llc | 1,789,306 | $44.1M |
| vivo capital, llc | 1,600,000 | $39.5M |
| commodore capital lp | 1,500,000 | $37.0M |
| caligan partners lp | 1,438,070 | $34.6M |
| balyasny asset management l.p. | 923,694 | $22.8M |
| logos global management lp | 915,000 | $22.6M |
| alyeska investment group, l.p. | 863,947 | $21.3M |
Showing top 10 of 72 institutional holders of LB PHARMACEUTICALS INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 13.1%
- Days to cover
- 9.9
- Shares short
- 3,110,447
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LBRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for LB PHARMACEUTICALS INC?
LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, LB-102, for the treatment of schizophrenia, with no approved products or revenue to date.
What is LB PHARMACEUTICALS INC's next catalyst?
LB PHARMACEUTICALS INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Ef" — expected October 1, 2027.
Who is the CEO of LB PHARMACEUTICALS INC?
Ms. Heather D. Turner Esq., J.D. is the chief executive officer of LB PHARMACEUTICALS INC (LBRX).
Where is LB PHARMACEUTICALS INC headquartered?
LB PHARMACEUTICALS INC (LBRX) is headquartered in New York, NY, United States.
What therapeutic areas does LB PHARMACEUTICALS INC focus on?
LB PHARMACEUTICALS INC develops therapies across Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.